Abstract:Glioblastoma (GBM) is a highly malignant, invasive, and poorly prognosed brain tumor. Unfortunately, active comprehensive treatment does not significantly prolong patient survival. With the deepening of research, it has been found that gut microbiota plays a certain role in GBM, and can directly or indirectly affect the efficacy of immune checkpoint inhibitors (ICIs) in various ways. (1) The metabolites produced by gut microbiota directly affect the host's immune homeostasis, and these metabolites can affect the function and distribution of immune cells, promote or inhibit inflammatory responses, affect the phenotype, angiogenesis, inflammatory response, and immune cell infiltration of GBM cells, thereby affecting the effectiveness of ICIs. (2) Some members of the gut microbiota may reverse T cell function inhibition, increase T cell anti-tumor activity, and ultimately improve the efficacy of ICIs by targeting specific immunosuppressive metabolites and cytokines. (3) Some members of the gut microbiota directly participate in the metabolic process of drugs, which can degrade, transform, or produce metabolites, affecting the effective concentration and bioavailability of drugs. Optimizing the structure of the gut microbiota may help improve the efficacy of ICIs. (4) The gut microbiota can also regulate immune cell function and inflammatory status in the brain through gut brain axis communication, indirectly affecting the progression of GBM and the therapeutic response to ICIs. (5) Given the importance of gut microbiota for ICI therapy, researchers have begun exploring the use of fecal microbiota transplantation (FMT) to transplant healthy or optimized gut microbiota to GBM patients, in order to improve their immune status and enhance their response to ICI therapy. Preliminary studies suggest that FMT may enhance the efficacy of ICI therapy in some patients. In summary, gut microbiota plays a crucial role in regulating ICIs in GBM, and with a deeper understanding of the relationship between gut microbiota and tumor immunity, it is expected to develop more precise and effective personalized ICI therapy strategies for GBM, in order to improve patient prognosis.

Modulation of the Immune Environment in Glioblastoma by the Gut Microbiota

Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review

Gut Microbiota in Brain Tumors: an Emerging Crucial Player.

Metabolic regulation on the immune environment of glioma through gut microbiota

Gut microbiota-mediated immunomodulation in tumor

Gut Microbiota’s Role in Glioblastoma Risk, with a Focus on the Mediating Role of Metabolites

Current understanding of the human microbiome in glioma

Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment

Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma

Csig-21. The Role Of Gut Microbiota In Glioblastoma: Insights From Microbiome-Gene Expression Interactions

The Gut Microbiota, Kynurenine Pathway, and Immune System Interaction in the Development of Brain Cancer

Exploiting the gut microbiome for brain tumour treatment

Exploring the gut microbiota and its potential as a biomarker in gliomas

The gut microbiome modulate response to immunotherapy in cancer

The Impact of Gut Microbiota-Derived Metabolites on the Tumor Immune Microenvironment

Gut microbiota alterations affect glioma growth and innate immune cells involved in tumor immunosurveillance in mice

The role of the gut microbiota in tumor, immunity, and immunotherapy

Therapeutic approaches to modulate the immune microenvironment in gliomas

Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect

The immunosuppressive microenvironment and immunotherapy in human glioblastoma

Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer